Skip to content

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-B )

Emergency Stroke Unit for Acute Cerebrovascular Events--A Prospective, Multicenter, Week-wise Randomized, Controlled Trial ( ESU-ACE-B )

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06492265
Enrollment
100
Registered
2024-07-09
Start date
2024-08-04
Completion date
2025-04-01
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke, Acute

Keywords

Emergency stroke unit, Low-field magnetic resonance imaging, Reperfusion therapy, Endovascular therapy

Brief summary

To compare the door-to-puncture time of patients with hyperacute ischemic stroke (between 4.5-6 hours after the onset of symptoms) treated in a standard stroke unit adherent to guidelines versus treated in Emergency Stroke Unit (a new stroke unit based on low-field magnetic resonance imaging).

Detailed description

Mechanical thrombectomy is an effective reperfusion therapy for patients with acute ischemic stroke due to large vessel occlusion. Faster door-to-puncture time (DPT) is associated with significantly better clinical outcomes. With the development of low-field magnetic resonance imaging, it is poised to play an increasingly significant role in the early diagnosis and management of acute ischemic stroke. This prospective, multicenter, week-wise randomized controlled trial will compare the door-to-puncture time of patients with hyperacute ischemic stroke (between 4.5-6 hours after the onset of symptoms) managed in a standard stroke unit adherent to guidelines versus managed in Emergency Stroke Unit (a new stroke unit based on low-field magnetic resonance imaging).

Interventions

The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.

The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.

Sponsors

Yongjun Wang
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 years; 2. Can be treated between 4.5-6 hours of symptoms onset\*(\*Symptom onset is defined by the last seen normal principle); 3. Presenting with ischemic stroke symptoms; 4. Pre-stroke mRS score 0-1; 5. Baseline NIHSS score ≥ 5; 6. Eligible for endovascular thrombectomy; 7. Informed consent signed.

Exclusion criteria

1. Baseline NIHSS score \< 5; 2. Unable to undergo MRI because of claustrophobia; 3. Patients with cardiac pacemaker/brain pacemaker/insulin pump implantation; 4. Definite contraindication for endovascular thrombectomy; 5. Patients with postictal hemiparesis (Todd's paralysis) or those with concomitant neurological/psychiatric conditions who are unable or unwilling to cooperate; 6. Pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of trial; 7. Participation in other interventional randomized clinical trials within 3 months before enrollment; 8. Patients deemed unsuitable for participation in this trial by the investigator or those for whom participation in this trial may result in greater risks.

Design outcomes

Primary

MeasureTime frameDescription
Door-to-puncture timeDoor-to-puncture timeThe time from emergency department arrival to the puncture of endovascular thrombectomy.

Secondary

MeasureTime frameDescription
Ordinal (shift) analysis of modified Rankin Scale (mRS) at 14±2 days (or at discharge, whichever occurs first).at 14±2 days (or at discharge, whichever occurs first).Ordinal (shift) analysis of modified Rankin Scale (mRS) at 14±2 days (or at discharge, whichever occurs first). Scores on the modified Rankin scale range from 0 (no neurologic deficit) to 6 (death).
Excellent functional outcome (Modified Rankin Scale score, mRS 0-1) at 14±2 days (or at discharge, whichever occurs first).at 14±2 days (or at discharge, whichever occurs first).Excellent functional outcome (Modified Rankin Scale score, mRS 0-1) at 14±2 days (or at discharge, whichever occurs first). Scores on the modified Rankin scale range from 0 (no neurologic deficit) to 6 (death).
Good functional outcome (Modified Rankin Scale score, mRS 0-2) at 14±2 days (or at discharge, whichever occurs first).at 14±2 days (or at discharge, whichever occurs first).Good functional outcome (Modified Rankin Scale score, mRS 0-2) at 14±2 days (or at discharge, whichever occurs first). Scores on the modified Rankin scale range from 0 (no neurologic deficit) to 6 (death).
The time from symptoms onset to endovascular thrombectomy decision.The time from symptoms onset to endovascular thrombectomy decision.
The time from emergency department arrival to endovascular thrombectomy decision.The time from emergency department arrival to endovascular thrombectomy decision.
The utility-weighted modified Rankin Scale (uw-mRS) at 14±2 days (or at discharge, whichever occurs first).at 14±2 days (or at discharge, whichever occurs first).The utility-weighted modified Rankin Scale (uw-mRS) at 14±2 days (or at discharge, whichever occurs first). Scores on the modified Rankin scale range from 0 (no neurologic deficit) to 6 (death).
Symptomatic intracranial hemorrhages (according to the ECASS III criteria) within 36 hours.within 36 hours.Symptomatic intracranial hemorrhages within 36 hours (sICH definition: according to the ECASS III criteria: any apparently extravascular blood in the brain or within the cranium that was associated with clinical deterioration, as defined by an increase of 4 points or more in the score on the NIHSS, or that led to death and that was identified as the predominant cause of the neurological deterioration).
Symptomatic intracranial hemorrhages (according to the ECASS III criteria) at 14±2 days (or at discharge, whichever occurs first).at 14±2 days (or at discharge, whichever occurs first).Symptomatic intracranial hemorrhages at 14±2 days (or at discharge, whichever occurs first) (sICH definition: according to the ECASS III criteria: any apparently extravascular blood in the brain or within the cranium that was associated with clinical deterioration, as defined by an increase of 4 points or more in the score on the NIHSS, or that led to death and that was identified as the predominant cause of the neurological deterioration).
Mortality at 14±2 days (or at discharge, whichever occurs first).at 14±2 days (or at discharge, whichever occurs first).
Adverse events at 14±2 days (or at discharge, whichever occurs first).at 14±2 days (or at discharge, whichever occurs first).
Serious adverse events at 14±2 days (or at discharge, whichever occurs first).at 14±2 days (or at discharge, whichever occurs first).
Door-to-reperfusion timeDoor-to-reperfusion timeThe interval between emergency department arrival and the vascular recanalization.

Countries

China

Contacts

Primary ContactYongjun Wang
yongjunwang111@aliyun.com59978555
Backup ContactJing Jing
jingj_bjttyy@163.com15810312511

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026